APA (7th ed.) Citation

X, M., P, V., DL, A., A, B., BAC, C., AH, C., . . . D, T. (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): Two multicentre, randomised, double-blind, active-controlled, phase 3 trials. The Lancet. Neurology, 23(11), 1119. https://doi.org/10.1016/S1474-4422(24)00328-4

Chicago Style (17th ed.) Citation

X, Montalban, et al. "Safety and Efficacy of Evobrutinib in Relapsing Multiple Sclerosis (evolutionRMS1 and EvolutionRMS2): Two Multicentre, Randomised, Double-blind, Active-controlled, Phase 3 Trials." The Lancet. Neurology 23, no. 11 (2024): 1119. https://doi.org/10.1016/S1474-4422(24)00328-4.

MLA (9th ed.) Citation

X, Montalban, et al. "Safety and Efficacy of Evobrutinib in Relapsing Multiple Sclerosis (evolutionRMS1 and EvolutionRMS2): Two Multicentre, Randomised, Double-blind, Active-controlled, Phase 3 Trials." The Lancet. Neurology, vol. 23, no. 11, 2024, p. 1119, https://doi.org/10.1016/S1474-4422(24)00328-4.